Stavudine resistance: An update on susceptibility following prolonged therapy

Antiviral Therapy

Volumn 4, Issue 1, 1999, Pages 21-28

  Lin, Pin Fang ^a   González, Charles J ^b   Griffith, Brigitte ^b,c   Friedland, Gerald ^b   Calvez, Vincent ^d   Perchai, Francoise ^e   Schinazi, Raymond F ^f   Shepp, David H ^g   Ashraf, Amar B ^g   Wainberg, Mark A ^h   Soriano, Vincent ⁱ   Mellors, John W ^j   Colonno, Richard J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f EMORY UNIVERSITY   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j VA Healthcare VISN 4   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; STAVUDINE;

ARTICLE; DRUG RESISTANCE; DRUG SENSITIVITY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG RESISTANCE; HIV-1; HUMANS; PHENOTYPE; RNA-DIRECTED DNA POLYMERASE; STAVUDINE;

EID: 0032898472     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Gulick RM. Current antiretroviral therapy: an overview. Quality of Life Research 1997; 6:471-474.
2. Morris-Jones S, Moyle G & Easterbrook PJ. Antiretroviral therapies in HIV-1 infection. Expert Opinion on Investigational Drugs 1997; 6:1049-1061.
3. Kuritzkes DR. HIV resistance to current therapies. Antiviral Therapy 1997; 2 (Suppl. 3):61-67.
4. Vacca JP & Condra JH. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997; 2:261-272.
5. Flexner D. HIV-protease inhibitors. Drug Therapy 1998; 338:1281-1292.
6. Larder BA & Kemp SD. Multiple mutations in the HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-1158.
7. Schinazi RF, Larder BA & Mellors JW. Mutations in retroviral genes associated with drug resistance. International Antiviral News 1997; 5:129-142.
8. Soriano V, Dietrich U, Villalba N, Immelmann A, Gil-Aguado A, Echevarría S, Clotet B, Ocaña I, Santamaría JM, Bouza E, Barona V, Gatell JM & González-Lahpz J. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997; 11:696-697.
9. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C & Wainberg MA. The same mutation that encodes low level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high level resistance to the (-)enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 1993; 37:1390-1392.
10. Schinazi RF, Lloyd RM Jr, Nguyen M-H, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ & Mellors JW. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy 1993; 37:875-881.
11. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J & Wainberg MA. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 1994; 38:275-281.
12. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N & Cameron J. Development of HIV-1 resistance to (-)2′-deoxy-3′tniacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9:351-357.
13. Schuurman R, Nijhuis M, van Leewen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J & Boucher CAB. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 1995; 171:1411-1419.
14. Richman D, Shih C-K, Lowy I, Rose J, Prodanovich P, Goff S & Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA 1991; 88:11241-11245.